Literature DB >> 27008250

Silk route to the acceptance and re-implementation of bacteriophage therapy.

.   

Abstract

This multidisciplinary expert panel opinion on bacteriophage therapy has been written in the context of a society that is confronted with an ever-increasing number of antibiotic resistant bacteria. To avoid the return to a pre-antibiotic era, alternative treatments are urgently needed. The authors aim to contribute to the opinion formation of relevant stakeholders on how to potentially develop an infrastructure and legislation that paves the way for the acceptance and re-implementation of bacteriophage therapy.
Copyright © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Year:  2016        PMID: 27008250     DOI: 10.1002/biot.201600023

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  21 in total

1.  Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host.

Authors:  Lauri Mikonranta; Angus Buckling; Matti Jalasvuori; Ben Raymond
Journal:  Biol Lett       Date:  2019-03-29       Impact factor: 3.703

2.  Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model.

Authors:  Archana Archana; Prem Shankar Patel; Rajesh Kumar; Gopal Nath
Journal:  Virusdisease       Date:  2021-03-10

3.  Phage therapy dosing: The problem(s) with multiplicity of infection (MOI).

Authors:  Stephen T Abedon
Journal:  Bacteriophage       Date:  2016-08-11

Review 4.  Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases.

Authors:  Andrzej Górski; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Wojciech Fortuna; Sławomir Letkiewicz; Paweł Rogóż; Ewa Jończyk-Matysiak; Krystyna Dąbrowska; Joanna Majewska; Jan Borysowski
Journal:  Front Microbiol       Date:  2016-09-26       Impact factor: 5.640

5.  Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial.

Authors:  Lorenz Leitner; Wilbert Sybesma; Nina Chanishvili; Marina Goderdzishvili; Archil Chkhotua; Aleksandre Ujmajuridze; Marc P Schneider; Andrea Sartori; Ulrich Mehnert; Lucas M Bachmann; Thomas M Kessler
Journal:  BMC Urol       Date:  2017-09-26       Impact factor: 2.264

6.  Bacterial competition and quorum-sensing signalling shape the eco-evolutionary outcomes of model in vitro phage therapy.

Authors:  Rachel Mumford; Ville-Petri Friman
Journal:  Evol Appl       Date:  2016-12-20       Impact factor: 5.183

7.  Biology and Genomics of an Historic Therapeutic Escherichia coli Bacteriophage Collection.

Authors:  Abiyad Baig; Joan Colom; Paul Barrow; Catherine Schouler; Arshnee Moodley; Rob Lavigne; Robert Atterbury
Journal:  Front Microbiol       Date:  2017-08-30       Impact factor: 5.640

8.  Editorial: Phage Therapy: Past, Present and Future.

Authors:  Stephen T Abedon; Pilar García; Peter Mullany; Rustam Aminov
Journal:  Front Microbiol       Date:  2017-06-15       Impact factor: 5.640

9.  Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome.

Authors:  Pikria Zhvania; Naomi Sulinger Hoyle; Lia Nadareishvili; Dea Nizharadze; Mzia Kutateladze
Journal:  Front Med (Lausanne)       Date:  2017-07-03

Review 10.  Modular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic Fibrosis.

Authors:  Victor Krylov; Olga Shaburova; Elena Pleteneva; Maria Bourkaltseva; Sergey Krylov; Alla Kaplan; Elena Chesnokova; Leonid Kulakov; Damian Magill; Olga Polygach
Journal:  Front Microbiol       Date:  2016-10-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.